Early Detection Research Network

Proteomic Panel for Lung Cancer

Aliases:
This biomarker is also known as:
  • Proteomic Panel for Lung Cancer,

Description…

An immunoaffinity-mass spectrometry-based quantification approach was used to develop an assay for verifying the expression of potential biomarkers in patient serum samples from lung cancer patients.

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Curated
HGNC Name:

Panel Details

The following organs have data associated with this biomarker…

Attributes

Phase: One
QA State: Curated

Overview

An immunoaffinity-mass spectrometry-based quantification approach was used to develop an assay for verifying the expression of potential biomarkers in patient serum samples.

Performance Comment

Researchers have developed an immunoaffinity-mass spectrometry-based approach using antibodies to enrich multiple proteins of interest from sera followed by LC-MRM-based quantification. As a proof of concept, it was demonstrated that CEA can be detected and quantified in a subset of patient sera. This is the first reported detection of CEA in sera using a mass spectrometry-based approach in serum samples. This method has allowed quantifying potential protein biomarkers in sera in the low ng/ml range with an acceptable CV. (From PMID:18388126)

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.

No other associated resources found.